Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

16 Apr 2025

Abstract excerpt

Parkinson’s disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns1–5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments6. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50–69) received bilateral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological disorders and treatments
Share to Neuroscience and Neural Engineering
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40240591
DOI: 10.1038/s41586-025-08700-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s diseasePMID 40240591Read ↗

Stem cell therapy for Parkinson’s disease: safety and modelingSemantic proximity Read ↗

Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s diseaseSemantic proximity Read ↗

Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challengesSemantic proximity Read ↗

Towards stem cell based therapies for Parkinson's diseaseSemantic proximity Read ↗

Advancing Parkinson’s disease treatment: cell replacement therapy with neurons derived from pluripotent stem cellsSemantic proximity Read ↗

Treatment of Parkinson's disease using cell transplantationSemantic proximity Read ↗

Using induced pluripotent stem cells for modeling Parkinson’s diseaseSemantic proximity Read ↗

Induced pluripotent stem cells and Parkinson's disease: modelling and treatmentSemantic proximity Read ↗

Organoid and pluripotent stem cells in Parkinson’s disease modeling: an expert view on their value to drug discoverySemantic proximity Read ↗

Modeling Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem CellsSemantic proximity Read ↗

Cell reprogramming therapy for Parkinson’s diseaseSemantic proximity Read ↗

Cell Therapy in Parkinson’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.